**Summary**
Anpario plc, a manufacturer of natural and sustainable feed additives for animal health, reported strong financial results for the year ended December 31, 2025. Key highlights include
**Revenue Growth** Revenue increased by 24% to ยฃ47.2 million, driven by the full-year contribution from the Bio-Vet acquisition and 12% like-for-like growth excluding Bio-Vet.
**Profitability Improvement** Gross margin improved to 50.9%, and profit before tax rose by 54% to ยฃ8.0 million. Adjusted EBITDA increased by 38% to ยฃ9.6 million.
**Earnings Growth** Basic earnings per share increased by 63% to 40.20p, and diluted adjusted earnings per share rose by 33% to 39.49p.
**Dividend Increase** The proposed final dividend increased to 8.90p per share, resulting in a total dividend for the year of 12.50p per share, an 11% increase.
**Operational Highlights** Successful integration of Bio-Vet, strong like-for-like sales growth across regions, and continued growth in premium product classes.
**Outlook** Trading in line with expectations, continued growth in North America, strong start in the Middle East, and efforts to mitigate the impact of the conflict in Iran on logistics and supply chains.
The companys performance reflects successful strategy execution, growing demand for natural feed additives, and operational leverage. Anpario remains focused on long-term profitable growth, innovation, and strengthening customer relationships, despite macroeconomic and geopolitical uncertainties.
Here is the HTML table code comparing the financials and debt year on year for Anpario PLC:
**Notes:** * The table compares key financial metrics for Anpario PLC between 2025 and 2024.
* All values are in millions of British pounds (ยฃm).
* The "Change" column shows the absolute difference between 2025 and 2024 values.
* The "% Change" column shows the percentage change between 2025 and 2024 values.
* Net Debt is calculated as Total Debt minus Cash and Cash Equivalents. Since Anpario PLC has no debt, Net Debt is equal to Cash and Cash Equivalents.